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Abstract Objective: To determine 
the effects of acute hypertonic man- 
nitol infusion on intravascular vol- 
ume expansion and to identify po- 
tential predictors of hypervolemia. 
Design: Measurements of plasma 
volume and volume regulatory hor- 
mones were performed in healthy 
volunteers before and over 90 min 
after acute infusion of 20 % manni- 
tol solution in a therapeutic dose of 
0.5 g/kg body weight, equalling an 
average infusion volume of 180 ml. 
Setting: Clinical research unit in an 
800-bed teaching hospital in the 
eastern part of Switzerland. 
Participants: Eight normal male vol- 
unteers. 
Measurements and results: Baseline 
plasma volume was determined by 
the indocyanine green dye dilution 
technique. Serial plasma protein 
measurements were performed after 
mannitol infusion to calculate intra- 
vascular volume changes. Mannitol 
administration resulted in a plasma 
expansion that persisted for more 
than 90 min and peaked at 112 % of 
the baseline plasma volume 15 min 
after infusion. Concomitantly, an in- 
crease in systolic blood pressure and 
a fall in plasma sodium concentra- 
tion occurred. Pharmacokinetic 
analyses of mannitol distribution 
and elimination revealed a close re- 
lation between plasma volume ex- 
pansion and mannitol serum con- 
centrations. While renin activity and 
aldosterone concentrations were 
suppressed proportionally to the in- 
travascular volume increase, antidi- 
uretic hormone was increased e- 
spite notable volume expansion and 
hyponatremia. Similarly, a rise in 
atrial natriuretic peptide was de- 
tected. 
Conclusions: Therapeutic doses of 
hypertonic mannitol cause substan- 
tial plasma volume expansion, re- 
sulting in increased blood pressure. 
Plasma volume expansion is related 
to mannitol serum concentrations 
and mannitol clearance determines 
the time required to restore normo- 
volemia. ADH and ANP are poten- 
tially aggravating factors of manni- 
tol-induced hyponatremia. 
Key words Mannitol- Volume 
expansion •Hormone 
response •Pharmacokinetics 
Introduction 
Mannitol is frequently employed in the setting of inten- 
sive care medicine, especially for the treatment of acute 
renal failure related to cardiovascular operations or se- 
vere traumatic injury, and to control cerebral edema. 
However, the administration of mannitol is associated 
with a number of serious side effects, such as volume 
overload, hyponatremia, metabolic acidosis, hyperkale- 
mia and acute renal failure [1, 2]. Since these adverse re- 
actions are probably the consequence of overdosing [3], 
they might be predictable, and thus preventable, if the 
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clinician could base his treatment on experimental data 
concerning the effects of mannitol. Most of these effects 
are secondary to the osmotic properties of mannitol in 
plasma and glomerular filtrate which cause an increase 
in plasma osmolality, extracellular fluid expansion, inhi- 
bition of renal sodium reabsorption and natriuresis [4]. 
The extent o which mannitol generates volume changes 
and electrolyte disorders and their pathophysiology are 
incompletely understood. The literature is scarce on 
studies that have examined these questions comprehen- 
sively. Serum concentrations of volume regulatory hor- 
mones such as ANP, vasopressin, renin and aldosterone 
are affected by acute mannitol admininistration [5-9], 
but their impact has never been investigated in relation 
to volume effects, mannitol concentrations and pharma- 
cokinetics. 
The aim of the present study was to quantify the 
short-term intravascular volume effect of a therapeutic 
mannitol dose in normal men. To define factors that pre- 
dict the time course of volume expansion and regression 
mannitol distribution and elimination were calculated 
from pharmacokinetic analyses. To further characterize 
the mechanisms that induce hypervolemia nd hy- 
ponatremia, we determined plasma concentrations of 
volume regulatory hormones uch as atrial natriuretic 
peptide (ANP), antidiuretic hormone (ADH),  plasma 
aldosterone (PA) and plasma renin activity (PRA) after 
mannitol administration. Our studies demonstrate that 
mannitol treatment causes ignificant alterations in vas- 
cular volume status with fluid shifts, accompanied by in- 
creased systolic blood pressure, a fall in plasma sodium 
concentrations and changes in hormone levels regulat- 
ing water homeostasis. Moreover, we demonstrate that 
mannitol serum concentration and clearance are the 
major determinants of its volume effects, whereas in- 
creases in ADH and ANP may contribute to the devel- 
opment of hyponatremia following mannitol infusion. 
Methods 
Subjects 
Experiments were performed in eight male, healthy volunteers 
(33 + 2 years old; 74.6 + 4.2 kg body weight; 182 + 3 cm height; 
1.90 + 0.07 m 2 body surface area). Participants were non-smokers, 
abstained from consuming coffee and alcohol, and confined their 
physical activity o a minimum the day prior to the experiments. 
None of the volunteers consumed any drugs. The experiments 
were carried out in the morning after an overnight fast. Water in- 
take was allowed until the beginning of the study. Urine collection 
was performed uring the 24 h before the start of the experiment 
to measure creatinine clearance. 
Procedure 
Volunteers at throughout the investigation. Two indwelling cathe- 
ters were placed, one in each arm, for separate infusions and blood 
sampling. Baseline parameters, including baseline plasma volume 
(PVbl), were determined 30 rain later. The infusion of mannitol 
was started 30 min after the completion f blood sampling for 
PV u calculation. Hypertonic mannitol (0.5 g/kg body weight, 
20% solution, corresponding to a volume of 2.5 ml/kg body 
weight) was administered intravenously over 10 min. Blood was 
drawn 15, 30, 45, 60 and 90 min after initiation of the infusion. 
The amount of blood drawn at each time point was replaced by in- 
fusion of isotonic sodium chloride. Blood pressure was determined 
in a sitting position at baseline, 15 min after mannitol administra- 
tion and at the end of the experiment. Urinary bladders were emp- 
tied 30 min before the infusions were started (to determine lec- 
trolytes and osmolality) and at the end of the experiment (to deter- 
mine creatinine, electrolytes andosmolality). 
Blood measurements 
Blood was collected in Vacutainer tubes for the determination f 
electrolytes, proteins, creatinine and osmolality [heparinized 
blood], as well as forplasma renin activity (PRA), plasma ldoster- 
one (PA) and antidiuretic hormone (ADH) [EDTA blood], and 
mannitol [whole serum]. For atrial natriuretic peptide (ANP) mea- 
surements blood was drawn manually into plastic syringes, to min- 
imize hemolysis, and transferred topolypropylene tubes contain- 
ing EDTA, to minimize adsorption on plastic surfaces. All tubes 
were immediately placed on ice and centrifuged within 15rain at 
3000 g and 4 °C for 10 min. Separated plasma for the determination 
of hormones was stored at-30 °C and analyzed within 8 weeks. The 
mannitol concentration in serum and urine was assessed bycapil- 
lary gas chromatography after derivatization with hexamethyldisi- 
lazan [10]. ANP was measured with a radioimmunoassay (RIA) 
using an antibody against he human c~ANP (Eiken Kogaku, To- 
kyo). ADH, PRA and PA were determined by RIA. Osmolality 
was measured with a Fiske osmometer (Vogel OM 801, Giessen, 
Germany), sodium and potassium with an ion selective lectrode 
(Hitachi 717) calibrated with a flame photometer. Creatinine was 
determined according to the modified Jaff6 reaction [11]. Protein 
concentrations to calculate plasma volume dilution were deter- 
mined by the Biuret method. The glomerular filtration rate 
(GFR) was estimated from creatinine clearance. 
Plasma volumes 
Baseline plasma volume (PVbl) was measured by using the indocy- 
anine green (ICG) dye dilution technique as described elsewhere 
[12]. ICG was administered in a concentration f 0.25 mg/kg body 
weight, and blood samples were drawn 2, 4, 6, 8 and 10 min after in- 
jection of ICG. Following centrifugation, 1.5ml plasma samples 
were measured photometrically (Perkin Elmers Lambda II) to cal- 
culate baseline plasma volumes. The expanded plasma volume 
(PVex.) after mannitol infusion was calculated by relating the base- 
line plasma protein concentration (PPb0 to the plasma protein con- 
centration [13] at time points 15, 30, 45, 60 and 90 min after the 
start of infusion (PP+,) using the formula PV exp= 
PP + nJ 
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Table 1 Summary of physical and chemical parameters deter- 
mined prior and after administration of mannitol. All values are 
means+SEM. All baseline measurements were performed 
30 min prior to administration ofmannitol. Serum mannitol, elec- 
trolyte and hormone concentrations were determined also at 15, 
30, 45, 60 and 90 min after start of mannitol infusion, and are pre- 
sented as relative changes from baseline (except for mannitol con- 
centrations). Blood pressure and urinary parameters are shown in 
absolute numbers, and were assessed at baseline and 90 rain after 
start of mannitol infusion (BP also after 15 min). Baseline creati- 
nine clearance isbased on a 24-h urine collection, which was com- 
pleted 30 min before mannitol infusion. Creatinine clearance at 
90 min was determined from blood and urine samples collected at 
the end of the experiment 
Normal range Prior to 15' 30" 45' 60' 90' 
(if applicable) Mannitol 
Serum mannitol conc. (mg/ml) 0.0 
Blood pressure (mmHg) 114.5 + 5.2 
Plasma volume (ml) 2.815 + 185 
Serum Na + (mmol/1) 130-145 140 + 1.0 
Serum K + (mmoI/1) 3.4-4.6 3.6 _+ 0.3 
Serum osmolality (mosmol/kg) 280-295 287.8 _+ 3.1 
ANP (pg/ml) [17 _+ 28 
ADH (pmol/1) 0-6.7 4.2 -+ 3.4 
Renin activity (pg/ml/h) 0.8-2.5 1.9 -+ 1.0 
Aldosterone (pg/ml) 20-120 95 _+ 49.0 
Urine volume (ml/h) 78 _+ 29 
Creatinine clearance (ml/min) 132 9145 3 
Urinary sodium (mmol/1) 59 +_ 19 
Urinary potassium (mmol/1) 61 -+ 27 
Urinary osmolality (mosmol/kg) 408 "+ 137 
2.6 + 0.2 1.85 ± 0.1 1.64 + 0.03 1.45 _+ 0.05 1.16 + 0.04 
122.3 + 2.8 - - - 114.3 _+ 4.5 
+ 341+ 50~ + 220-+451t +201+43t  + 186+49~ +135-+465 
-4.4-+ 0.6t - 3.4 9145 0.5t -2.4 _+ 1.2~. -2.6-+ 0.3t -2 .0+ 1.5t 
+ 0.05 + 0.0 + 0.1 + 0.15 + 0.1 
+3.25_+1.9 +3.6_+1.5~ +4.5 +1.3~- + 3.75_+ 1.4t +2.0_+1.1 
+0.0 +13+4§  +17-+5§ +14_+7 +12_+8 
+ 0.8-+ 0.37:~ - - +0.1-+0.55 - 
-0.56 + 0.17~ -0.74_+0.17§ - 0.55 -+ 0.24 -0.7_+0.2§ -0.5_+0.14§ 
-37-+ 16:I -43-+ 151: -47_+ 16 .~ -50_+ 16~ -55+16:~ 
. . . .  287 + 21 "~ 
. . . .  135 _+ 4 
. . . .  63 "+6 
. . . .  28"+5 
. . . .  54O + 46 
9: P at least < 0.01; ~: p at least < 0.05; §: p at least < 0.02 
Pharmacokinetic calculations 
Plasma concentration-time curves were analyzed model-indepen- 
dently. The terminal elimination half-life was calculated from the 
slope of the terminal elimination phase @) after semilogarith- 
mic transformation asfollows: tl/2 = ~.  The total plasma clear- 
A dose ance (CL) of administered mannitol was calculated as CL = 
A UC' 
where dose is the mannitol dose infused and AUC the area under 
the plasma concentration-time curve. AUC was calculated by the 
trapezoidal rule as follows: AUC=AUC(O- t )  + c_~), where 
AUC(0-t) is the area from time 0 to the last time point when a plas- 
ma sample was obtained and C(t) the plasma concentration at this 
time point. The volume of distribution at steady state was calculat- 
AUMC 
ed as: Vss = dose A UC 2 ' with AUMC being the area under the 
first moment concentration-time curve, calculated according to 
Shumaker [14]. 
The s tudy  protoco l  was  approved  by the  hosp i ta l ' s  E th ic  Com-  
mi t tee .  All volunteers gave written informed consent. 
Statistical analyses 
The results are given as means + standard error of the mean 
(SEM). Statistics were performed on absolute values by analysis 
of variance for repeated measurements (ANOVA). Correlation 
between the different variables was estimated by regression analy- 
sis. Probability values less than 0.05 were considered statistically 
significant. To account for interindividual variability of baseline 
concentrations, the results for hormone analyses are also presented 
as mean percentage change from baseline (in the text and Fig. 1B- 
F). 
Results 
A summary of all results is given in table 1. 
Mannitol  concentrat ions and kinetics 
Infusion of mannitol  in a therapeutic dose (20 % solu- 
tion, 0.5 g/kg body weight) over 10 min resulted in a 
peak serum concentrat ion of 2.6 + 0.25 mg/ml after 
15 min (Fig. 1A). El imination occurred in a biphasic 
manner  with a slightly slower decrease in serum concen- 
trations after 30 min, resulting in a terminal tl/2 of 
79 + 7 min. Mannitol  plasma clearance equalled 
142 _+12 ml/min. The volume of distribution was 
15.4 + 1.1 1, reflecting the penetrat ion of mannitol  across 
the vascular compartment  into the interstitium. 
Effects on plasma volume, blood pressure and urine 
excretion 
In order to assess the volume effect of 180 + 9 ml hypero 
tonic mannitol  solution, plasma volumes were deter- 
mined at baseline before the administration of mannitol  
by the indocyanine green dye dilution technique (PVbl). 
Changes in plasma volumes 15, 30, 45, 60 and 90 min af- 
ter the start of infusion were calculated from baseline 
values and changes in plasma protein concentrat ions at 
the respective time points (Pvex p + n)" Infusion of a thera- 
peutic dose of mannitol  resulted in a maximal plasma 
volume increase of 341 + 44 ml or 112.2 + 1.5 % of base- 
line volumes 15 min after the start of infusion (p < 0.001; 
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Fig.IA-F Changes in serum mannitol concentrations (A), plasma 
volume expansion (B) and endocrine response (PRA (C), PA 
(D), ADH (E), and ANP (F)) after intravenous administration f 
mannitol: All values are means + SEM. Except for mannitol con- 
centrations (absolute values), numbers are presented as mean per- 
cent changes from baseline (= 0). Time points are indicated as rain 
after start of infusion, which was completed at 10 min. Mannitol 
concentrations at all time points: p < 0.001 vs. baseline (all statisti- 
cal analyses were performed on absolute numbers). Arrow (1") in- 
dicates Tm for mannitol: p t at least < 0.05; :~: p at least < 0.02 
Fig.lB). Concomitantly, blood pressure rose from 
114.5 + 5.2 to 122.3 + 2.8 mmHg, but returned to base- 
line values at 90 min after start of mannitol administra- 
tion (114.3 + 4.5 mmHg). In order to determine the 
specificity of the blood pressure response to mannitol, 
isotonic NaC1 was infused to the same volunteers in a 
separate experiment and in an even larger volume 
(420 + 25 ml) than the resulting plasma expansion from 
mannitol. Unlike the reactions to mannitol, systolic 
blood pressure was virtually unchanged by the adminis- 
tration of saline (116.5+4.6mmHg before, and 
116.3 + 3.8 mmHg 15 min after infusion of NaCI: 
p < 0.01 vs increase in systolic blood pressure after man- 
nitol). Mannitol infusion yielded a urinary volume pro- 
duction of 431 + 31 ml over 90 min, increasing the urine 
flow from 78 + 29 to 287 + 21 ml/h (p < 0.0001). It is 
noteworthy that volume expansion lasted for more 
than 60 min, the time point where the increase in plasma 
volume equalled the volume of infused mannitol. 
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Even after 90min, when volunteers had excreted 
more then 400 ml of urine, plasma volumes were still 
135 +46ml  above baseline values (Fig.lA). As for 
the elimination of mannitol, a biphasic curve was 
found for regression of the mannitol-associated increase 
in plasma volume. The initial transcellular volume shift 
(Vshift) induced by mannitol can be estimated from the 
product of the percent change in serum sodium concen- 
tration at 15 min and the estimated volume of extracel- 
lular water (ECV=20% of body weight): 
Vshi  f l  = [NaO][NaO]- [Nal5] •ECV = 140-135.6140 0.2 - 751 
= 0.465 1. 
Plasma osmolality 
As anticipated, mannitol significantly raised plasma os- 
molality from 288 + 1.1 to 293 + 1.2 mosmol/kg (Ta- 
ble 1). Whereas time-matched correlations between 
changes in plasma osmolality following mannitol infu- 
sion and intravascular volume expansion missed statisti- 
cal significance (r = 0.32, p < 0.08), significant correla- 
tions were found when the changes in plasma volume 
were matched with osmolality changes at the preceding 
time point. For example, volume expansion determined 
30 rain after the beginning of mannitol infusion corre- 
lated significantly with changes in osmolality measured 
15 min earlier (r = 0.82, p < 0.05). Similarly, the increase 
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in plasma volume after 90 min was strongly correlated 
with the increase in osmolality at 45 rain from infusion 
(r = 0.94, p < 0.01). Of interest is the fact that mannitol 
concentrations were significantly and positively corre- 
lated with intravascular volume expansion (r = 0.45, 
p < 0.02). 
Effect on plasma sodium 
Plasma sodium was significantly lowered by mannitol 
during the whole experiment, reaching minimal concen- 
trations 15 rain after the start of infusion (Table 1). 
Endocrine response 
Plasma renin activity and aldosterone concentrations 
were lowered significantly after volume expansion due 
to mannitol (Fig. 1C and D). The mean percentage de- 
creases from baseline for PRA ranged between 25 + 5 
(t = 15 rain) and 37 + 3 (t = 30 min); and for PA between 
34 + 9 (t = 30 rain) and 50 + 9 (t = 90 min). 
Despite the marked plasma volume expansion occur- 
ring after its administration, mannitol "paradoxically" 
increased plasma concentrations of ADH by a mean 
percentage of 54 _+ 28 at 15 min (p < 0.05) and 28 _+ 41 
at 60 min from baseline (Fig. 1E). Moreover, the in- 
crease in ADH concentrations after mannitol infusion 
correlated positively with the early changes in plasma 
osmolality (r = 0.73, p = 0.04) but was unrelated to 
changes in plasma volumes. Finally, ANP concentra- 
tions after mannitol infusion were significantly elevated 
by a maximum mean percentage of 23 + 11 over base- 
line at 45 min @ = 0.02; Fig. 1F). Unlike ADH, the en- 
docrine response of ANP after mannitol infusion was in- 
dependent of changes in serum osmolality. 
Discussion 
In this study we induced and quantified substantial vol- 
ume expansion in normal subjects with a pharmacologi- 
cal dose of hypertonic mannitol solution. This was ac- 
companied by an increase in systolic blood pressure 
and decreased sodium concentrations. We have further 
elucidated eterminants hat may account for some of 
mannitol's adverse ffects. 
Volume overload is among the most serious side ef- 
fects resulting from mannitol. The mean infused volume 
of mannitol (180 ml) in our experiments caused an in- 
travascular volume expansion of up to 341 ml which 
peaked at 15 min and persisted for the length of the 
study (Fig. 1B). The total intravascular volume shift 
(Vshift) induced by I80 ml of infused mannitol (Vinf) was 
465 ml. The calculated volume effect (Vef0 of mannitol, 
expressed as Vef = Vshift+Vi,,f Vi,,f was 358 %, or about 3 
times the administered volume load. The hemodynamic 
impact of this volume effect is underlined by the ob- 
served increase in systolic blood pressure that occurred 
even in our normal volunteers. This effect coincided 
with the greatest degree of intravascular volume expan- 
sion by mannitol. Such a short-term volume load may 
significantly compromise the hemodynamic capacity, in 
particular when projected to patients with impaired car- 
diac or renal function. 
Changes in intravascular volume status were closely 
related to serum osmolality and serum mannitol concen- 
trations. A tight relationship between the serum manni- 
tol concentration and the plasma volume expansion is 
further supported by the similar shape of the time 
curves of the plasma volume and the mannitol serum 
concentration, with a change in their slope after 
30 min. Moreover, our pharmacokinetic data suggest 
that the regression of plasma expansion is mainly deter- 
mined by the serum tl/2 of mannitol, which averaged 
79 min. The regression rate of volume expansion be- 
tween 15 and 90 min after mannitol infusion equals 
0.6 %/min. At 79 min after mannitol infusion, the vol- 
ume expansion was still 52 % of the initially observed in- 
crease, which is close to the 50 % decrease of the manni- 
tol serum concentration atthis time point (Fig. 1A). 
To further elucidate the mechanisms that cause hyp- 
ervolemia, increased blood pressure and hyponatremia, 
we investigated the endocrine response to mannitol ad- 
ministration. Whereas the observed ecrease in plasma 
renin activity and plasma aldosterone concentrations is 
most likely secondary to the mannitol-induced plasma 
volume expansion, the changes in ADH and ANP re- 
quire further consideration. It is noteworthy that an in- 
crease in ADH after mannitol occurred in the presence 
of hyponatremia and hypervolemia. This response is at- 
tributable to the increase in osmolality and/or plasma 
mannitol concentrations. As the osmoregulatory mech- 
anism is not equally sensitive to all plasma solutes [9], 
the resulting stimulatory effect of mannitol and its con- 
secutive rise in serum osmolality was more potent han 
the inhibitory effects of hyponatremia and plasma vol- 
ume expansion. The fact that mannitol increases ADH 
concentration i  the face of a fall in plasma sodium con- 
centration could aggravate mannitol-induced hy- 
ponatremia clinically, as collecting duct water reabsorp- 
tion would be expected to be stimulated espite volume 
expansion and hyponatremia in this setting. Finally, 
mannitol increased ANP concentrations, most likely by 
volume expansion, which is the main stimulus for ANP 
release [15]. This increase in plasma ANP has to be con- 
sidered with regard to the effects of ANP on urinary 
electrolyte handling. It is well established that ANP in- 
creases renal sodium excretion in a concentration-de- 
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pendent manner [16]. Moreover, an additive effect of 
ANP and mannitol on sodium excretion in dogs has 
been described when they were infused together [17]. 
Consequently, the mannitol-induced rise in plasma 
ANP concentrations may contribute to the natriuresis 
and hyponatremia resulting from mannitol administra- 
tion. 
What are the clinical implications of our findings? 
The present data indicate that severe hypervolemia and 
detectable hyponatremia occur after mannitol adminis- 
tration, even in healthy subjects. It is likely that these f- 
fects are even more pronounced in patients with im- 
paired cardiac and renal function prone to develop se- 
vere hypervolemia nd hyponatremia. However, our 
pharmakokinetic determinations have shown that man- 
nitol clearance from the serum determines the regres- 
sion of intravascular volume expansion, and thereby 
normalization of volume status. Moreover, our experi- 
ments suggest hat repetitive determinations of serum 
osmolality are valuable in is predicting the extent of vol- 
ume expansion from mannitol treatment and detecting 
patients that warrant special attention. To further evalu- 
ate the impact of adapted mannitol treatment, clinical 
studies based on the present results are suggested in se- 
lected clinical settings. From a pathophysiological point 
of view, the present study proposes a potential role for 
ADH and ANP in the development of hypervolemia 
and hyponatremia resulting from mannitol infusion. 
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